Please login to the form below

Not currently logged in
Email:
Password:

Meda

This page shows the latest Meda news and features for those working in and with pharma, biotech and healthcare.

Mylan agrees to buy Sweden's Meda for $7.2bn

Mylan agrees to buy Sweden's Meda for $7.2bn

Mylan agrees to buy Sweden's Meda for $7.2bn. Deal is set to boost its over-the-counter medicines portfolio . ... Adding Meda enhances Mylan's presence in attractive markets such as China, Southeast Asia, Russia, the Middle East and Mexico, said Bresch.

Latest news

  • Meda collaborates on asthma comic book Meda collaborates on asthma comic book

    Meda collaborates on asthma comic book. Launches new Explain Asthma volume at ACAAI annual meeting. ... Meda and Medikiz have launched a new volume in a series of educational healthcare comic books for children.

  • Cancer drugs lead SMC recommendations Cancer drugs lead SMC recommendations

    People with acne also have access to another treatment after the positive recommendation for Meda Pharmaceuticals' Treclin (clindamycin / tretinoin), while the SMC also gave the green light to the orphan drug

  • Meda agrees $3.1bn takeover of Italy's Rottapharm Meda agrees $3.1bn takeover of Italy's Rottapharm

    Meda agrees $3.1bn takeover of Italy's Rottapharm. Will gain specialty medicines and boost its emerging market presence. ... which complement Meda's own operations in countries such as China and Brazil.

  • Sanofi won't take part in mega-deal trend Sanofi won't take part in mega-deal trend

    Meanwhile, rising Canadian company Valeant is also said to be interested in a $45bn merger with Allergan and generics firm Mylan is attempting to buy Swedish company Meda for $9bn.

  • Mylan raises offer for Meda to $9bn Mylan raises offer for Meda to $9bn

    Mylan raises offer for Meda to $9bn. US generics looks to increases broaden portfolio with Swedish firm. ... The current flurry of merger activity in the drug industry shows no sign of abating, with Mylan making a $9bn bid for Swedish rival Meda.

More from news
Approximately 6 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2016 Deal Watch February 2016

    The deal value is approximately $9.9bn when including Meda's net debt, which represents a multiple of around 12.9 x 2015 adjusted EBITDA. ... Licensor Acquired/Licensee Acquirer. Product/Technology. Deal Type. Headline ($m). Meda/Mylan. portfolio of

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    5, 300. Rottapharm/ Meda. Company acquisition . Portfolio of Rx and consumer products.

  • Pharma deals during May 2014 Pharma deals during May 2014

    in Europe, Meda (rejected bid from Mylan), AMco and previously Nycomed (now owned by Takeda).

  • Deal Watch table for August 2013 Deal Watch table for August 2013

    180. GardenHills /. Veropharm. Acquisition. Generic drug manufacture. 151. Acton Pharmaceuticals / Meda.

  • Pharma deals during May 2013 Pharma deals during May 2013

    And, on top of that, at the end of the month there were rumours circulating that the Indian generic company Sun Pharma is seeking to buy Meda for around $5bn. ... Meda's expansion has also been driven by product acquisitions and in the process incurred $2

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Henrik Stenqvist joins Recipharm Henrik Stenqvist joins Recipharm

    Henrik Stenqvist joins Recipharm. Was previously CFO for Meda Group. Recipharm appoints Henrik Stenqvist as its new executive VP and chief financial officer, bringing 24 years of finance and management experience. ... Prior to joining Recipharm,

  • Virgo makes consumer health changes Virgo makes consumer health changes

    include Durex, Nurofen and Meda Pharma.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Solaris Health

    GlaxoSmithKline. Ipsen. Meda. PM Society. Santhera. Visufarma. See our Thought Leadership article reviewing pressures at both end of the cost spectrum and considering the likely impact on clinicians and patients.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics